Trial Profile
A multicentre trial to evaluate the predictive and prognostic role of Mecasermin (IGF-I) in patients with primary epithelial ovarian cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2016
Price :
$35
*
At a glance
- Drugs Mecasermin (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 28 Mar 2016 New trial record
- 01 Mar 2016 Results published in the Anticancer Research